Resources

In part 2 of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the complexities of managing diabetes, including in pediatric patients.

In part 3 of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the use and concern about the CGM in managing pediatric diabetes.

In part 4 of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the use of the latest diabetes technology in his practice.

In part 5, the conclusion of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about what he wants healthcare practitioners to understand about transitioning pediatric patients and his goals for his patients' A1C.

In part 4 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the joint effects of SGLT-2 and PCSK9 inhibitors.

In this week's Homerun Slides, inflammation and immune issues.

Links between diabetes and cancer: common risk factors

Epidemiologic studies demonstrate that those with diabetes are more likely to develop cancer, but the mechanisms through which this may occur are incompletely understood. The American Diabetes Association and the American Cancer Society published a consensus report in 2010, with the aim of examining the knowledge regarding the association between diabetes and cancer, exploring the risk factors for both conditions, to examine their possible biologic links and to determine whether certain treatments for diabetes modify cancer risk.

Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.